Let’s look at a couple of ‘integrated’ mHealth applications.
Earlier, I briefly reviewed Proteus Digital Health’s ingestible sensor. This week Proteus announced that they had concluded a US$62.5 million financing. I found the following statement in the news release to be particularly interesting:
“Proteus Digital Health is working to create a new category of products, services and data systems that have the potential to significantly improve the effectiveness of existing pharmaceutical treatments, leading to fundamentally new care paradigms.”
“By embedding Proteus technology into established, market leading products & services we are changing healthcare and empowering patients, physicians and researchers with digital technology.”
But, Proteus’ technology may be especially applicable during the clinical development of new pharmaceutical treatments, so the participation of Oracle, which provides clinical trial management software, is noteworthy. Oracle made a news release on their investment, which explained:
“Oracle and Proteus expect to work together in clinical trials exclusively to provide clinical investigators worldwide the ability to measure information about medication ingestion, dose timing, and associated physiologic response continuously and precisely for patients enrolled in clinical trials.
The two companies are expected to integrate Proteus’ ingestible sensor with Oracle’s leading clinical trial products, such as Oracle Health Sciences InForm, Oracle Life Sciences Data Hub and Oracle’s Siebel Clinical Trial Management System, using the secure, reliable and scalable Oracle Health Sciences Cloud.”
The integration aspect of this study was that the WellDoc system was combined with Allscripts EHR (electronic health records) so patient data could be shared bi-directionally.
“The integration must take into account each user’s day-to-day life and workflow, including patients, providers, IT staff, and additional caregivers.”
Proteus leverages pharmaceutical products, while WellDoc leverages an existing IT solution tp gain early, commercial traction.